[Special Stock] Daewoong Pharmaceutical's 'Hoistar Tablet' Surges on Confirmed COVID-19 Treatment Effectiveness
[Asia Economy Reporter Kum Boryeong] Daewoong Pharmaceutical's stock price surged on the 10th as it promoted the treatment effects of 'Hoistar Tablet' for the novel coronavirus infection (COVID-19).
At 9:15 AM that day, Daewoong Pharmaceutical's stock price was 132,000 KRW, up 12.82% (15,000 KRW) compared to the previous trading day.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Daewoong Pharmaceutical announced the day before that, after prescribing Hoistar Tablet to mild COVID-19 patients in Korea, it confirmed the regulation of inflammatory responses and suppression of fever symptoms.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
